ReviewFrontiers in immunology2026

Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy.

Xinwang Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.